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A comparative study evaluating C-reactive protein, sputum 
eosinophils and forced expiratory volume in one second 
in obese and nonobese asthmatics
Abstract
Introduction: Asthma and obesity are considered inflammatory disorders. Inflammatory markers — sputum eosinophils, 
C-reactive protein (CRP) and the forced expiratory volume in one second (FEV1) were analysed to find their association in obese 
asthmatics and compared with their asthma control test (ACT) to understand these parameters in this phenotype.
Material and methods: After completing the asthma control test (ACT), the CRP, FEV1 and sputum eosinophils of sixty asthmat-
ics were compared to find the association of them in obese and nonobese asthmatics and contrasted with their ACT. The data 
were analysed using IBM SPSS V20.0, Mann-Whitney U test (non-parametric test), Pearson’s correlation coefficient and Fisher’s 
exact test.
Results: We found significant differences for CRP (P = 0.001) and sputum eosinophils (P = 0.001) between obese and nonobese 
asthmatics, both higher in obese asthmatics and with a significant association with body mass index (BMI) (P < 0.05). The FEV1 
levels were independent of the BMI levels of asthmatics. There was a significant correlation between the CRP and sputum eosin-
ophils (0.52, P = 0.001) for all asthmatics. There was no significant correlation between FEV1 and sputum eosinophils (nonobese 
P = 0.120, obese P = 0.388) and between FEV1 and CRP (obese P = 0.423, nonobese P = 0.358) in both obese and nonobese 
asthmatics. Obesity had an association (P = 0.001) with ACT scores (≤ 19).
Conclusions: Sputum eosinophils and CRP were raised in obese asthmatics and had a positive association with BMI. Obese 
asthmatics had a poorer subjective asthma control than nonobese asthmatics despite FEV1 being independent of the BMI levels. 
Measuring the systemic inflammatory markers could help in additional interventions in reducing systemic inflammation and thus 
possibly facilitating better symptom control.
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Introduction
Asthma is a syndrome characterised by recur-
rent episodic airway obstruction, airway inflam-
mation and bronchial hyper-responsiveness. It is 
a syndrome with a variety of phenotypes, where 
various precipitating factors result in clinical, 
physiological and pathological manifestations. The 
main pathogenesis of asthma is the infiltration of 
inflammatory cells such as eosinophils, basophils, 
and CD4 + lymphocytes in the airways [1, 2].
Obesity is also considered an inflammatory 
disorder conveyed by various systemic inflam-
matory mediators like C-reactive protein (CRP) 
that leads to an increase in circulating levels 
of the pro-inflammatory cytokines. CRP is also 
raised in various systemic inflammations such 
as diabetes, cardiovascular diseases, collagen 
vascular diseases, malignancies, and also obesity 
[3–5]. Various studies have shown that severe 
asthma is more prevalent in obese patients as 
compared with patients with normal body mass 
index (BMI) and that BMI is positively associated 
with asthma severity [6]. Also, BMI correlates 
positively with the level of asthma control, with 
more severe asthmatics having a higher BMI than 
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those with milder asthma [7, 8]. Thus, obesity 
seems to be related with asthma severity, but the 
mechanisms responsible for this relationship are 
not yet clarified.
There is growing evidence that asthma and 
obesity are strongly associated with each other 
and can alter each other’s status [9]. Also, the 
inflammatory cells, sputum eosinophils and 
interleukin-5 play a major role in airway inflam-
mation in asthmatics, more so in obese asthmat-
ics who are already in a pro-inflammatory state 
[10]. Evidence of neutrophilic inflammation of 
the airways in obese asthmatics has also been 
documented [11], but the association between 
the non-neutrophilic airway inflammation in 
obesity, the systemic inflammation and the lung 
function remains poorly understood, especially 
in different phenotypes and endotypes of asthma. 
As the treatment of asthma has evolved from 
the airway obstruction-based approach to a tai-
lored-endotype and phenotype-based approach, 
especially in special subsets of asthma like the 
obese phenotypes, it helps to know the relation-
ship between the inflammatory markers both 
systemic (CRP) and airway (sputum eosinophils), 
with the forced expiratory volume in one second 
(FEV1) in this regard. 
As our understanding of various subtypes 
of asthma has evolved over years, here we try 
to evaluate the obese asthmatic subtype and the 
inflammatory markers associated with both the 
airway (sputum eosinophils) and systemic marker 
(CRP), and correlate them with their lung func-
tion (FEV1) and compare the same with nonobese 
asthmatics. This might help us to understand 
the systemic inflammatory component of asth-
ma, specifically concerning the obese asthmatic 
phenotype and the markers associated with it. 
Correlating these inflammatory markers with the 
patient’s subjective control of symptoms through 
the asthma control test (ACT) could give us a bet-
ter understanding of the roles these inflammatory 
markers play in the symptom control.
The purpose of this cross-sectional study 
was to evaluate the systemic inflammation using 
CRP, airway inflammation by measuring sputum 
eosinophils and the measure of lung function by 
FEV1 in obese and nonobese asthmatics, compare 
and correlate these parameters between the obese 
and nonobese groups. We also try to ascertain 
whether there is a significant association between 
the inflammatory markers (sputum eosinophils, 
CRP) amongst each other and with FEV1 and to 
compare BMI with the asthma control test (ACT) 
scores. 
Materials and methods
Sixty asthmatic patients who presented to 
the outpatient department of Respiratory Medi-
cine, in Sree Balaji Medical College and Hospi-
tal, Chennai. were recruited for the study from 
2018 to 2019. We aimed to compare and evaluate 
CRP, FEV1 and sputum eosinophils in obese and 
nonobese asthmatics and to find the association 
of CRP, FEV1, and sputum eosinophils among each 
other and compare BMI with the asthma control 
test scores (ACT) [12].
Patients with a primary diagnosis of asthma 
according to the Global Initiative for Asthma 
(GINA) guidelines, 18 years of age or older were 
included in this study. Individuals with nonre-
versible airway obstruction on spirometry (< 12% 
change in FEV1) who were unable to do spirom-
etry due to a history of myocardial infarction, 
congestive heart failure, coronary artery disease, 
who had a history of smoking, with known co-
morbidities like diabetes, cardiovascular diseases, 
collagen vascular diseases and malignancies were 
excluded from the study.
All the patients who satisfied the inclusion 
criteria, filled up the asthma control test and were 
later told to do pulmonary function test — spi-
rometry, serum CRP and sputum sample after 
deep coughing in a sterile container. Then sputum 
quality was assessed using both macroscopic and 
microscopic criteria [13]. Sputum was stained 
with eosin and haematoxylin and analysed using 
microscopy to determine the count of eosinophils 
expressed in percentage, and counts ≥ 3 % was 
considered to be high [14], BMI ≥ 30 kg/m2 were 
considered obese, and CRP > 1 mg/dL was con-
sidered high-risk. The ACT is a patient-completed 
questionnaire for individuals above 12 years of 
age and consists of five items evaluating the pre-
ceding 4 weeks (limitation of activities, shortness 
of breath, awakenings at night, use of reliever 
medication and patient’s perception of asthma 
control). Each question has five response options, 
resulting in scores of 1–5. The sum of all scores 
yields the total ACT score, a score of less than 
equal to 19 indicates poorly controlled asthma, 
and a score greater than equal to 20 indicates 
good asthma control, the maximum being 25. All 
the participants had forced expiratory volume 
1 second/functional vital capacity (FEV1/FVC) 
< 70% with post-bronchodilator reversibility 
FEV1 > 12% on spirometry. 
Statistical analysis: A total of 60 patients 
were included in the study. The data were an-
alysed using IBM SPSS V 20.0. Mann-Whitney 
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U test (non-parametric test) was performed for 
comparing outcome variables between obese and 
nonobese groups, Pearson’s correlation coeffi-
cient was computed to measure the association 
of the outcome variables amongst each other and 
Fisher’s exact test was used to find the associa-
tion of BMI with the asthma control test score. 
P-value < 0.05 was considered to be statistically 
significant.
Results
There were a total of 60 subjects. Among 
them, the number of males were 22 (37%) and fe-
males were 38 (63%). The mean age was 41.48 (SD 
= 10.98). All of the participants were classified 
as obese (BMI ≥ 30) and nonobese (BMI < 30) 
(Table 1). Among the 60 subjects, 32 were obese 
and 28 were nonobese (Table 1). 
We found statistically significant differences 
in CRP (P = 0.001) and sputum eosinophils (P = 
0.001) between obese and nonobese asthmatics 
(Table 1). We noted that the median CRP was 
higher, 2 mg/dL for obese asthmatics compared to 
1 mg/dl for nonobese asthmatics (Table 1, Figure 1). 
Also, the same trend was reflected in median spu-
tum eosinophils, being 6% for obese asthmatics 
and 2% for nonobese asthmatics (Table 1, Figure 2). 
However, we did not find any significant differ-
ence in FEV1 between obese and nonobese asth-
matics (P = 0.882) (Table 1).
Among the associations between the param-
eters themselves (Table 2), we observed that there 
was a significant correlation between the CRP 
and sputum eosinophils (0.52, P = 0.001) for all 
asthmatics (Figure 3). We found no significant 
correlation between FEV1 and sputum eosinophils 
(nonobese P = 0.120, obese P = 0.388) and also 
between FEV1 and CRP (obese P = 0.423, nonobese 
P = 0.358) in both obese and nonobese asthmat-
ics. Comparing the BMI with the asthma control 
test scores (Table 3), we noticed that asthma was 
not controlled (ACT scores ≤ 19) for 94% of obese 
asthmatics as compared to only 25% for nonobese 
asthmatics, and there was a significant association 
(P = 0.001) between obesity (BMI) and ACT scores.
Table 1. Comparison of outcome variables between obese and nonobese asthmatics. Values presented as median with 
interquartile range in parenthesis. *Mann-Whitney-u non-parametric test; P value < 0.05 — statistically significant
Outcome Non-obese (N = 28) Obese (N = 32) P value*
CRP 1 (0–1) 2 (1–4) 0.001
FEV1 60 (59–70) 64 (55–71) 0.882
Sputum eosinophils 2 (2–3) 6 (4–7) 0.001
CRP — C-reactive protein; FEV1 — forced expiratory volume in one second
Figure 1. Comparison of C-reactive protein between obese and non-
obese asthmatics. BMI — body mass index
Figure 2. Comparison of sputum eosinophils between obese and 
nonobese asthmatics
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Discussion
This study aimed to compare the CRP, 
FEV1 and sputum eosinophils in obese and non-
obese asthmatics and to ascertain whether there 
is an association between the groups. We also 
sought to find a link between the inflammatory 
markers — CRP and sputum eosinophils and 
FEV1, and also among each other in asthmatics 
and correlate it with asthma control test scores. To 
the best of our knowledge, this study is one of the 
very few studies done to compare the various in-
flammatory markers in both obese and nonobese 
asthmatics and probably the first study to try to 
find an association between the inflammatory 
markers themselves and with the BMI. We also 
tried to correlate the inflammatory markers with 
the self-perception of symptom control through 
the asthma control test. 
With our data, we found that median CRP 
and sputum eosinophils were higher in obese 
asthmatics than in nonobese asthmatics. Also, 
CRP and sputum eosinophils had a positive as-
sociation with BMI. However, the FEV1 did not 
correlate positively with BMI. Our findings were 
in concordance with the findings of Van Veen et 
al. regarding FEV1 that has not decreased in obese 
asthmatics and has not shown a significant dif-
ference between obese and nonobese asthmatics 
[15]. Interestingly, our study was in contrast to the 
other finding reported in the same study wherein 
the authors showed that obese asthmatics do not 
have more airway inflammation as compared with 
nonobese asthmatics. But in our study, sputum 
eosinophils and CRP were also found to be higher 
in obese asthmatics and had a positive correlation 
with each other for all asthmatics.
Obese asthmatics had a significant associa-
tion with asthma control test scores, predominant 
number of obese asthmatics (94%) had uncon-
trolled ACT (score ≤ 19). Even if the FEV1 was 
independent of the BMI levels, our patients who 
were obese had an increased perception of symp-
toms reflected through the poor asthma control 
scores of less than equal to 19. An increase in 
systemic inflammation in obesity has been well 
described [16]. It has been suggested that high lev-
els of pro-inflammatory molecules released from 
adipose tissue into the systemic circulation could 
Table 2. Association between outcomes in obese and nonobese asthmatics
  Outcome FEV1 Sputum eosinophils
Non-obese (N = 28) Correlation* CRP 0.069 0.080
P value 0.358 0.337
Correlation* FEV1 -0.221
P value 0.120
Obese (N = 32) Correlation* CRP -0.037 0.301
P value 0.423 0.053
Correlation* FEV1 -0.054
P value 0.388
All samples (N = 60) Correlation* CRP -0.012 0.520
P value 0.464 0.001
Correlation* FEV1 -0.082
P value 0.268
*Pearson correlation coefficient. P value < 0.05 — statistically significant. CRP — C-reactive protein; FEV1 — forced expiratory volume in one second
Figure 3. Association between C-reactive protein and sputum eosin-
ophils in all asthmatics
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contribute to the airway inflammation, thus in-
creasing the prevalence and poor asthma control 
in obese asthmatics [17]. In our study, CRP levels 
were found to be elevated in obese asthmatics 
and this probably explains that this pro-inflam-
matory state could lead to increased perception 
of symptoms. The inflammatory markers (CRP 
and sputum eosinophils) were independent of 
the FEV1 in all asthmatics, and thus perception 
of breathlessness reflected by the poor asthma 
control test scores (ACT ≤ 19) in these obese phe-
notypes of asthmatics could indeed be caused by 
the systemic inflammation. Many other studies 
have also demonstrated a positive correlation 
between elevated CRP levels and asthma control, 
respiratory impairment and bronchial hyper-re-
activity [18–21].
Among the associations between the inflam-
matory mediators themselves, the CRP and spu-
tum eosinophils showed a positive correlation in 
all asthmatics. Our study was in agreement with 
a similar study by Abdelsadek et al. who showed 
a positive correlation with CRP and sputum eosin-
ophils in asthmatics [22]. In this study, however, 
the BMI wasn’t correlated with the inflammatory 
markers. The mechanism of airway inflammation 
is complex in obese asthmatics. It can be mediat-
ed through various inflammatory mediators like 
interleukin (IL)-4, IL-5, IL-13, inflammatory cells 
like eosinophils, mast cells and basophils to name 
a few apart from the possible overlay of systemic 
inflammation. Non-eosinophilic inflammation 
and systemic inflammation could also play an 
important role in airway inflammation in obese 
asthmatics.
 Obesity has been demonstrated to be a risk 
factor for asthma and is associated with an in-
creased prevalence of asthma symptoms [23, 
24]. But this, whether it is because of systemic 
inflammation, airway constriction or the change 
in dynamics of respiration and the restrictive 
defect or a contributory factor of both, needs to 
be investigated. 
As the asthma treatment guidelines are evolv-
ing from a symptom-based approach to a tailored 
approach, it will be wise to optimise the treatment 
based on various phenotypes and endotypes, and 
thus probably reducing an impending exacerba-
tion. Interestingly, many studies have previously 
shown that treating the airway inflammation led 
to better asthma control and thus, in turn, reduced 
hospitalisations and fatal events [25], and if the 
treatment strategy is aimed at keeping sputum eo-
sinophils low, patients might have fewer asthma 
exacerbations [26]. Since elevated CRP is often 
associated with accelerated lung function decline 
[27], aiming at the treatment based on markers 
of inflammation both the airway and systemic 
inflammation is a more scientific and rational 
approach than treating the physiological effects 
caused by it, which is particularly relevant, espe-
cially in obese asthmatics. These obese asthmatics 
who have an overlay of systemic inflammation 
could also be phenotyped as a separate entity. 
In our study, the CRP and sputum eosinophils 
were higher in obese asthmatics, which suggests 
concordance between these biomarkers; and simi-
larly to treating the airway inflammation, whether 
treating the systemic inflammation in these obese 
phenotypes leads to better asthma control, needs 
to be examined. Thus, the measure of systemic 
inflammatory markers in obese asthmatics with 
poor disease and symptom control plays an im-
portant role, and this should help to ascertain the 
systemic mediator’s role and thus help to devise 
a treatment plan for these subsets of patients. This 
should ideally include rigorous weight manage-
ment plans apart from pharmacological interven-
tions in obese asthmatics which aim at reducing 
the systemic inflammatory mediators like the 
CRP levels. This might yield a better asthma con-
trol wherein the contributors of breathlessness 
can also be caused by restrictive lung defect in 
obesity. Apart from their airway inflammation, 
measuring the systemic inflammation adds a de-
finitive value in difficult to treat obese asthmat-
ics with poor symptom control. It is hoped that 
these results will help to understand the systemic 
inflammation of the obese phenotype of asthma 
and provide better asthma management. Serial 
measurements of CRP, sputum eosinophils and 
FEV1, additional interventions and follow-ups 
Table 3. Association between body mass index (BMI) and asthma control test (ACT)
Non-obese (BMI < 30) Obese (BMI ≥ 30) P-value*
Asthma not controlled (ACT ≤ 19) 7 (25) 30 (94)
0.001
Asthma controlled (ACT > 19) 21 (75) 2 (6)
Numbers with percentage in parenthesis. *Fisher’s exact test; P value < 0.05 — statistically significant
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could have given us more insights into these 
parameters in different disease states and during 
various levels of asthma controls. 
Conclusions
Thus, the inflammatory markers sputum 
eosinophils and CRP were raised in obese asth-
matics and had a positive association with BMI. 
Obese asthmatics had a poorer subjective asthma 
control than the nonobese asthmatics despite 
FEV1 being independent of the BMI levels. Mea-
suring the systemic inflammatory markers in 
obese asthmatics who do not have adequate sub-
jective symptom control reflected by uncontrolled 
ACT scores, could add a definitive value and 
possibly help in additional interventions aimed at 
reducing systemic inflammation and facilitating 
better symptom control.
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